Wolff Schmiegel

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · The Lancet · 2019 · 2.4K citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +9

Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

Eric Van Cutsem, Chris Twelves, Jim Cassidy et al. · Journal of Clinical Oncology · 2001 · 1K citations

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

Michael A. Nauck, Ulrich Niedereichholz, Rainer Ettler et al. · American Journal of Physiology-Endocrinology and Metabolism · 1997 · 812 citations

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 713 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +12

Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Mieke Schutte, Ralph H. Hruban, Joseph Geradts et al. · PubMed · 1997 · 665 citations

Tumor Biology, Pancreatic Cancer, Medicine +13